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ABSTRACT
Schizophrenia (SCZ) is a major debilitating, complex, and costly illness that strikes 1% of the world’s population. It is characterized by three general 
types of symptoms: Atypical symptoms (aggressiveness, agitation, delusions, hallucinations), depressive symptoms (alogia, avolition, anhedonia, 
apathy), and cognitive symptoms (impaired attention, learning, memory). The etiology of SCZ has still not been fully understood. Alteration in various 
neurochemical systems such as dopamine, serotonin, norepinephrine, gamma-aminobutyric acid, and glutamate are involved in the pathophysiology 
of SCZ. The lack of understanding regarding the exact pathogenic process may be the likely a reason for the non-availability of effective treatment, 
which can prevent onset and progression of the SCZ. The tools of modern neuroscience, drawing from neuroanatomy, neurophysiology, brain imaging, 
and psychopharmacology, promise to provide a host of new insights into the etiology and treatment of SCZ. In this review, we will discuss the role of 
the various neurotransmitter concerned and brain parts exaggerated in the SCZ.
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INTRODUCTION
Schizophrenia (SCZ) is categorized by a spectrum of symptoms that 
characteristically consist of chaotic thinking, societal withdrawal, 
hallucinations (both acoustic and optical), delusions of persecution 
(suspicion), and peculiar manners. These symptoms are sometimes 
considered as “positive” (such as hallucinations) and “negative” (such as 
communal departure and lethargy). SCZ is a common and devastating 
disease which is categorized by chronic psychotic symptoms and 
psychosocial destruction [1]. An understanding of the pathophysiology 
of SCZ will be important to the invention of an anticipatory method and 
healing intervention. Rapidly advancing research into SCZ includes diverse 
etiological hypothesis and offers instructions for prospect investigate and 
treatments [2]. SCZ is a constant and distressing neuropsychiatric disorder 
affecting 1% of the world population. It is associated with disturbances 
in social performance and has high suicidal rates leading to personal and 
family suffering. In psychiatric disorders, improper alterations in cortical 
circuitry and synaptic transmission in the developing brain occurs due to 
primary alterations in the activity of these molecules, which could then 
translate into the neural dysfunction [3].
The onset of the disease occurs mainly in late adolescence and 
adulthood. There is certain evidence, which signifying the susceptible 
genes and environmental risk factors associated with the SCZ and 
how these interactions between them self-leading to the progression 
of disease. All these evidence have supported the fact that there are 
deficits during neurodevelopment that is the main root cause of 
the pathophysiology of the disease [4,5]. The risk factors operate 
synergistically with both neurodevelopment and glutamate-associated 
signaling [6]. The characteristic feature of the disease is intense 
and long-lasting impairments mainly in language, memory, and 
cognition, as well as the brain regions, subserving these domains are 
affected structurally and functionally [7]. It imposes an excessively 
large financial load in terms of hospitalization, chronic treatment, 
psychotherapy, and lost efficiency [8]. Males are more vulnerable to SCZ 
rather than females which start from mid to late adolescence through 
early adulthood [9]. During the premorbid stage of the disease, minor 
physical anomalies and subtle motor, societal, or cognitive impairments 
are often observed. However, these differences commonly fail to place 
persons outside the regular range of performance. Attenuated positive 
symptoms, mood symptoms, cognitive symptoms, societal withdrawal, 
or obsessive activities may arise in the prodromal stage [10,11]. It is a 
remarkable challenge for the scientific community represented by SCZ, 
which produces the human suffering, family tragedies, and financial 
burden [9]. Even though some insights into the etiology of SCZ have been 
developed, an indulgent of the disease on the molecular level remains 
indescribable. Thus, essential avenues characterized by neuroanatomy, 
neurophysiology, brain imaging, and psychopharmacology during 
modern investigation [10].
CLINICAL FEATURES OF SCZ
SCZ is a destructive ill health that strikes at some of the highly developed 
functions of the human brain. Psychotic or “positive” symptoms 
(aggressiveness, agitation, delusions, and hallucinations), deficit or 
“negative” symptoms (alogia, avolition, anhedonia, and apathy), and 
cognitive dysfunction (impaired attention, learning, and memory) are 
three main categories of symptoms. The psychotic symptoms of SCZ are 
a feature of many brain diseases but are often the most disturbing and 
noticeable symptom to others. Hallucinations, delusions, and thought 
disorder are three main categories included in psychotic symptoms. 
The rigorous disturbances in social relations, enthusiasm, expression 
of affect, ability to understanding enjoyment, and natural tongue 
considered under the negative symptoms [12,13]. Elite functions 
such as concentration, memory, and general cerebral performance are 
affected by cognitive disfigurement in SCZ. The psychotic symptoms 
have an episodic pattern, but the negative and cognitive symptoms are 
more persistent and chronic and when active is usually the impetus for 
hospitalization [14,15].
During the first 5-10 years, both positive symptoms such as delusions, 
hallucinations, negative symptoms like impaired cognition, decision, 
sensation and  deterioration of the substantial functions such as 
work, interpersonal relationships as usually occurs after the onset 
of full syndrome. Fuzzy disturbances in the form and content of 
thought, observation, cognition, feeling, sense of self, desire, social 
relationships, and psychomotor behavior which further defines SCZ 
characteristically [16].
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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•	 Symptoms	of	a	acute	episode	may	include	the	following:	Being	out	
of touch with actuality; hallucinations (particularly hearing voices); 




lack of support, lack of sympathy, and orally or bodily violence: 
Impaired self-cured skill; and distressed sleep and hunger [13].
•	 The	patient	usually	has	 remaining	 character	 (e.g.,	 nervousness,	
suspiciousness, lack of desire, lack of enthusiasm, poor insight, 
impaired judgment, societal extraction, complexity in wisdom from 
understanding, and poor personality skills), after the acute psychotic 
episode [12]. The various clinical features of SCZ are summarized in 
Fig. 1 [12].
Neurotransmitter hypothesis of SCZ
There are a number of theories of SCZ, dominated for many years 
by neuropharmacology, that implicate aberrant neurotransmission 
systems, in particular, aberrant dopaminergic, serotoninergic, and 
glutamatergic systems. It is unclear; however, to what extent any 
neurochemical findings reflect primary rather than secondary pathology, 
compensatory mechanisms, or environmental influences [15,23,24]. 
Certain studies have suggested that dysregulation of dopaminergic, 
gamma-aminobutyric acid (GABA), glutamatergic neurotransmission, 
and their interactions are involved in the pathophysiology of 
SCZ [25-27]. Neurotransmitters and the pathogenesis of SCZ are 
summarized in Table 1.
Dopaminergic hypothesis
Psychoses may result from hyper- or hypoactivity of dopaminergic 
processes in specific brain regions. This may comprise the presence of 
a dopamine (DA) receptor defect. The dopaminergic hypothesis of SCZ 
considers that an improper dopaminergic transmission at the dopamine 
D2 receptor in the mesolimbic and prefrontal brain regions is responsible 
for schizophrenic symptoms mainly positive [24]. In spite of having 
several limitations until now, this hypothesis remains the prominent 
neurochemical theory. There is certain evidence such as dopamine 
presynaptic storage dysfunction, abnormal vascular transport, release, 
reuptake, and metabolic abnormality in the mesolimbic dopamine 
system, which suggests the involvement of presynaptic dopaminergic 
abnormality in the illness. Dysregulation and hyperresponsiveness of 
presynaptic dopamine neurons further induce oxidative stress which 
may lead to long-lasting consequences. As a result, dopamine activity 
may be decreased in the neocortex, responsible partially for negative 
symptoms such as emotional or cognitive impairment [11].
GABAergic inhibitory input that arises from the ventral pallidum is 
considered to be the most potent input to the dopaminergic neurons. 
Dopaminergic projections that are linked to SCZ which involved in the 
mesocortical system. This system arises in the ventral tegmental area 
(VTA) and projects to numerous cortical areas including mainly the 
prefrontal cortex, anterior cingulate cortex (ACC), and the temporal 
lobes. Abnormality in dopaminergic signaling, as well as the mesolimbic 
and nigrostriatal projections, is likely to be involved in SCZ [28].
The dopamine levels are found to be enhanced in the substantia 
nigra and the striatum of the basal ganglia, the levels found to be 
decreased in the cortex of schizophrenic patients. In neuroleptic-naive 
patients, changes in dopamine synthesis, storage, and release results 
in an overactive striatal dopaminergic system [29]. The high striatal 
dopamine function has been strongly linked to motor dysfunction 
and psychotic symptoms [30]. The D1 and D2 dopamine receptor 
abnormality, likely thought to be responsible for some of the abnormal 
behavioral and motor symptoms seen in SCZ [31].
Fig. 1: Clinical features of schizophrenia
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This hyperstimulation is thought to result from highly sensitive D2 
receptors, antipsychotic drugs (amphetamine or methylphenidate) 
exacerbated psychotic symptoms in SCZ patients [32]. In the nigrostriatal 
projection, dopamine is produced and synthesized in the substantia 
nigra, in turn stimulating movement through D1 receptors. Dopamine 
by binding to the D2 receptors via the GABA neurons which inhibits the 
indirect pathway and suppresses movement [33].This indirect pathway 
begins with cortical excitation of the striatal neurons and excites the 
GABA neurons, discrete from those that are excited in the direct pathway. 
The neurons in the substantia nigra are projected and inhibit the motor-
related functions of the thalamus. The balance between two conjugate 
pathways is needed for normal motor function [34]. There are four main 
dopamine pathways in the brain.  The mesolimbic system concerned 
with the addiction, emotion, perception & pleasure and reward-seeking 
behaviors, cognition. The mesocortical pathway involved in attention, 
emotional behavior, learning, and memory. The nigrostriatal pathway 
implicated in movement and sensory stimuli and tubuloinfundibular 
pathway for the control of inhibition of the prolactin hormone secretions 
and functions of the hypothalamic–pituitary endocrine systems. The 
pathways of dopamine in brain and SCZ are summarized in the Fig. 2 [35].
The dopamine hypothesis of SCZ proposed that the positive symptoms 
of the illness arose as a consequence of the hyperactivity of the 
dopaminergic system, in the mesocortical and mesolimbic area of the 
brain whose origin lies in the VTA. The dopamine hypothesis has been 
made to reconcile by focusing on other neurotransmitters that may 
interact with dopamine in discrete cortical and subcortical neural 
circuits. Dopamine heteroreceptors have been suggested to regulate the 
release of glutamate in the striatum; this finding is an evidence for the 
hypothesis which suggests the involvement of abnormal levels of both 
glutamate and dopamine in the corticostriatal Pallidal thalamic circuit in 
the etiology of SCZ. Along with the dopamine-glutamate abnormality in 
the corticostriatal systems, the possible involvement of other subcortical 
regions has also accounted for schizophrenic symptoms. The important 
area of the brain involved in new memory formation, information 
processing, and generation of specimen-specific behaviors are 
hippocampus and entorhinal cortex. Morphological and cytoarchitecture 
abnormalities in these areas of the brain have been suggested for the 
positive symptoms of SCZ. Hippocampus and entorhinal cortex are 
innervated by the dopaminergic system, while glutamate is considered 
to be the predominant intrinsic excitatory neurotransmitter. Thus, the 
positive symptoms of the illness may be considered to be related to the 
hippocampus dopamine–glutamate system dysfunction [12].
Brain-derived neurotrophic factor (BDNF)
BDNF has been associated with the pathophysiology of SCZ. However, 
it is not clear whether alterations in BDNF observed in schizophrenic 
patients are a core part of disease neurobiology or a result of 
treatment. The neurotrophic factors, such as nerve growth factor, 
BDNF, neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT4/5) support 
the development, differentiation, and survival of nerve cells during 
growth and are also involved in the maintenance and flexibility of adult 
neurons [36].
Dopamine (DA) has been strongly having a major role in the 
pathophysiology and management of SCZ. There are several studies, 
which show an interactions between BDNF and the DA system. In the cell 
cultures from embryonic rat and human ventral mesencephalon, BDNF 
reduces the loss of tyrosine hydroxylase and protects dopaminergic 
neurons from neurotoxic agents such as 6-hydroxydopamine and 
1-methyl-4-phenylpyridinium [37]. It has been reported by several 
studies that there is a significant reduction in serum BDNF levels of 
chronic and medicated schizophrenic patients compared to healthy 
volunteers [38].
Serotoninergic system
Recent focus has been changed toward the involvement of serotonin 
(5-hydroxytryptamine, 5-HT) in the pathophysiology of SCZ [39]. 
Serotonin is an essential neurotransmitter synthesized from dietary 
tryptophan. The possible role of serotonin in SCZ was first recognized 
in the 1950’s when serotonin was noticed to be similar to lysergic 
acid diethylamide (LSD). LSD competes for and occupies serotonin’s 
receptor sites with very high potency, resulting in the development 
of psychosis-like symptoms. The hypothesis was supported by the 
fact that typical antipsychotics, when used in combination with a 
5-HT2 antagonist such as ritanserin resulted in a considerable relief 
of patient’s negative symptoms and motoric side effects. 5-HT2A 
receptor regulation appears essential for many of the features of the 
atypical antipsychotic drugs. All atypical antipsychotic drugs have 
been shown to have a favorable 5-HT2A/D2 affinity ratio in vitro and 
in vivo. The number of cortical 5-HT2A and 5-HT1A receptors is altered 
in schizophrenic brains [40]. 5-HT2C receptor antagonists are likely to 
produce weight gain and possibly seizures [18]. Certain polymorphisms 
of the 5-HT2A receptor gene are associated with SCZ; the trophic role 
of serotonin in neurodevelopment may be usurped in SCZ; 5-HT2A 
receptor-mediated activation of the prefrontal cortex may be impaired 
in some schizophrenics, and serotoninergic and dopaminergic systems 
are interdependent and may be simultaneously affected in SCZ [39]. 
Newer antipsychotic drugs are targeting serotonin receptors, and so 
the system is being studied for SCZ. Decreased in the cortical 5-HT2A 
receptor concentration and increased in the 5-HT1A receptor density 
have been reported in SCZ [41,42].
Glutamatergic system
Glutamate is the most abundant amino acid neurotransmitter in 
the mammalian brain. There are two types of glutamate receptors: 
Metabotropic and ionotropic receptors. The ionotropic receptors 
are subdivided into three subtypes and are the major focus in SCZ: 
N-methyl-D-aspartate (NMDA), quisqualate/gamma-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid (amino-3-hydroxy-5-methyl-
isoxazole-4-propionic acid [AMPA]), and kainate [43]. However, the 
NMDA receptor (NMDAR) is the most studied and relevant receptor 
subtype to understand the pathophysiology of SCZ. The NMDA receptor 
plays an important role in neurocognition and toxicity [44]. The 
NMDAR D-serine/glycine site on the NR1 subunit is not fully saturated 
at synapses in brain regions such as the prefrontal cortex, neocortex, 
hippocampus, thalamus, and brainstem slices, suggesting that agonists 
of the D-serine/glycine site are capable of regulating NMDAR-mediated 
neurotransmission [45]. Glycine is a major inhibitory neurotransmitter 
throughout the brain. The synapses are extensively reorganized during 
postnatal brain development up to young adulthood. NMDA receptor also 
plays a key role in the major changes of reorganization of glutamatergic 
synapses [46]. NR2A and NR2B subunits have dissimilar conductance 
and calcium permeability. NR2A and NR2B subunits are highly expressed 
Table 1: Neurotransmitters and the pathogenesis of SCZ
Neurotransmitters Action of NT Brain part involved Receptors References
Dopamine Increase/decrease Mesolimbic (positive symptoms) and 
mesocortical (negative symptom) 
D2 and D4 [17]
Serotonin Increased Prefrontal cortex (negative symptoms) 5-HT2A and 5-HT1A [18,19]
Glutamate Glutamate receptor binding 
changes
Prefrontal cortex, thalamus, and hippocampus NMDA [20,21]
GABA Decrease Limbic and prefrontal cortical GABA A [21,22]
GABA: Gamma-aminobutyric acid, NMDA: N-methyl-D-aspartate, SCZ: Schizophrenia
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in the forebrain corticolimbic regions and undergo a developmental 
shift: Switching progressively from richness in NR2B subunits in 
the early postnatal brain into richness in NR2A subunits during 
development [47]. A major role of this shift is to change the threshold 
for modifying synaptic power. Therefore, the ratio of NR2A/NR2B has 
a significant contribution in the development of cortical functions [48]. 
This developmental switch results in changes in brain plasticity and 
synaptic transmission [49]. One more important neurodevelopmental 
process is “synaptic pruning,” in which synapses are reorganized into 
more competent configurations, including glutamatergic synapses. 
Much evidence suggests that hypofunction of NMDA receptor-mediated 
neurotransmission is a significant deficit in SCZ [50]. Effects on different 
symptom domains of SCZ such as negative symptoms, cognitive deficits, 
and quality of life, except neurotransmission, synaptic flexibility, 
memory, and cognition are also regulated by the NMDA receptor. Thus, 
reduction of NMDA receptor-mediated neurotransmission may result in 
loss of neuronal plasticity and cognitive deficits [51].
The dopaminergic and glutamatergic system of the brain are 
interconnected, and thus, inhibition of one system will influence the 
functioning of the other system [52]. The NMDA receptor antagonist 
diminishes the corticofugal inhibition of subcortical dopamine neurons 
and hence enhances dopaminergic transmission [53]. It was concluded 
by PET studies that acute administration of NMDA-receptor antagonists 
increases dopamine release in the striatum and chronic administration 
elicits decreased dopamine release or hypoactivity in the prefrontal 
cortex [54]. AMPA and kainate receptors are non-NMDA glutamate 
receptors that get overactivated by NMDA receptor. Glutamate 
release as a response to NMDA receptor antagonists might in part be 
responsible for their behavioral effects. NMDA receptor hypofunction 
may alter synaptic connectivity leading to abnormality [35,55].
NMDA
Abnormality in the dopamine levels in schizophrenic brain remains 
highly pertinent to deficits in reward response, novelty detection, 
attention, and neuroplasticity [56,57]. Unusual dopamine signaling 
is a consequence of many other primary modulatory abnormalities, 
including NMDAR dysregulation [58]. Among relevant receptor systems, 
NMDARs have drawn maximum attention due to historical observations 
that the NMDAR antagonist phencyclidine produces a syndrome in 
healthy individuals which resembles SCZ. Electrophysiological findings 
provide additional support for a link between NMDA and GABA in 
SCZ, as reduced NMDAR depended on inhibitory drive results in the 
increased excitability that characterizes SCZ [59].
Acetylcholine
Neurotransmitter acetylcholine controls the activity of the cholinergic 
system in the central nervous system (CNS) and is important in many 
functions such as learning and memory [60]. Acetylcholine functions by 
activating two families of receptors, the nicotinic receptors which are 
ligand-gated ion channels and muscarinic receptors which a G-protein-
coupled receptors [61]. There are five types of muscarinic (M1-M5) 
receptors and all are present in the human CNS but are expressed 
in a different way on CNS regions and different cells and capable of 
controling different CNS functions [62]. The belief that muscarinic 
receptors were involved in the pathophysiology of SCZ came from early 
clinical neuropsychopharmacological studies. It was the demonstration 
that in the caudate-putamen from patients with schizophrenia (3H) 
pirenzepine binding was less [63]. It was a good an effort in better 
understanding the role of muscarinic receptors in the pathophysiology 
of SCZ. The lower levels of (3H) pirenzepine binding were also reported 
in the cortex and hippocampus in schizophrenic patients. It is therefore 
significant that it is lower levels of muscarinic M1 receptor (CHRM1), 
that accounts for the decreased levels of (3H) pirenzepine binding in 
the cortex of patients with SCZ [64,65].
Cognitive and neurological abnormalities in SCZ
SCZ is associated with defective memory, attention, executive, 
and intellectual impairment [66,67]. Yet, a gracious literature has 
emphasized that dysfunction in basic motor function and control 
represents an extremely pertinent physiological pathway in the 
disease [68]. The motor dysfunction in SCZ is more direct, showing 
the impairments in basic motor processing and control. Medial 
orbitofrontal cortex and rostral part of the ACC (rACC) were responsible 
for emotional processing and decision-making, as well as playing an 
important role in social behavior and interaction. It was supported by 
the evidence that the brain regions such as the dorsal ACC, the basal 
ganglia, and the cerebellum, which are associated with memory and 





Fig. 2: Major pathways for the dopaminergic system in the brain and schizophrenia
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There are several evidences which indicate that the brain’s limbic 
system is involved in SCZ. In addition, the dopaminergic mesolimbic 
tract (originates in the VTA of the midbrain and projecting to a number 
of limbic regions) is considered to play a most important role in the 
development of positive psychotic symptoms of SCZ. The neuroleptic 
drugs show improvement of the psychotic symptoms by blocking D2 
receptors in the limbic structures [71]. There is a reduction in volume of 
limbic structures in SCZ and histological abnormalities are seen in medial 
temporal lobe structures, that is, the hippocampal formation, amygdala, 
and adjacent cortical areas [72]. The gray matter volume decreases 
in medial temporal lobe and an increase of the temporal horn of the 
lateral ventricles [73]. There is an increase and decrease in metabolic 
activity in the medial temporal lobe regions of schizophrenics [74]. 
The abnormalities include a decrease in area or whole volume of the 
hippocampus as well as in the number of hippocampal neurons, reduced 
neuronal size and density, and pyramidal cell disarray, the majority of 
cases consistent with hippocampal sclerosis [75]. The various brain 
parts and its features are shown in Fig. 3 [76].
SCZ is a “thought disorder,” and thinking has been conceptualized as an 
“active motor process.” The basal ganglia are considered as cognitive and 
motor pattern generators [76]. It generates sequences of action which 
designs the future action. Schizophrenic patients with motor abnormalities 
predict deficits in memory, decision-making, and concentration [77]. 
The corticocerebellar inhibition of the motor cortex is important in 
the coordination of motor sequences, which has been suggested to be 
impaired in various findings. Thus, cerebellar organization influences 
the fidelity of perceptions, error detections, and quick modulation 
of coordination [78]. SCZ may impair these functions of cerebellum 
resulting in misinterpretation of incorrect sensory associations usually 
suppressed by the cerebellum, resulting in the repeatedly noted evidence 
of anomalous prophetic coding in the illness [79].
The basal ganglia play a role in sequencing the activation for fast actions 
by balancing movement and muscle activation [80]. Connections to 
the corticopontocerebellar system make the cerebellum which a main 
control area for voluntary motor control, enhances the structures 
relevance for SCZ [81]. The main output center of the cerebellum is the 
dentate nucleus, which links premotor, prefrontal, posterior parietal 
and primary motor cortex mainly through the thalamus. These areas 
of cortex sends back the projections for the processing through pons. 
These corticocerebellar loops link function of the cerebral cortex to the 
cerebellum and vice versa. The cerebellum is thought to act as a timer, 
updating and predicting body dynamics for fast movements based on 
sensory feedback, and this precision is assumed to have high temporal 
fidelity [82-84].
Fig. 3: Brain parts involved in schizophrenia
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Wide range of neurotransmitters’ receptors (biogenic amines, amino 
acids, and neuropeptides) exists in the hippocampus, as well as other 
medial temporal cortical regions.
The prefrontal cortex is an area that is known to be concerned with 
executive functioning and it is well-known fact that these functions 
are impaired in SCZ [85]. Many studies also suggest the hyperactivity 
of hippocampus in SCZ [86]. The hippocampal formation is site of 
memory and learning. It has a major role in the medial temporal–
diencephalic–basal forebrain system that mediates the compilation 
of short-term memory into long-term memory, thus it enables the 
attainment and preservation of novel information [87]. Schizophrenic 
patients show abnormal learning and memory performance related to 
verbal and visual material which is similar to temporal lobe epilepsy. 
SCZ is associated with hippocampal volume reduction, most of the 
neuroimaging studies had failed to express an association between 
long-term memory and hippocampal or temporal lobe volume 
reduction in schizophrenic patients indicating that non-hippocampal 
brain regions (e.g., cerebellum, thalamus, prefrontal, and parietal 
association cortex) play a major role in the cognitive deficits that 
characterize schizophrenia [88,89]. Schizophrenic symptoms produced 
by different brain parts abnormality are discussed in Table 2.
CONCLUSION
SCZ is a chronic heterogeneous syndrome of disorganized and bizarre 
thoughts, delusions, hallucinations, inappropriate affect, and impaired 
psychosocial functioning. SCZ is likely a neurodevelopment disorder that 
may also think to be affected by ongoing changes in the brain structure. 
The tools of modern neuroscience, drawing from neuroanatomy, 
neurophysiology, brain imaging, and psychopharmacology, promise 
to provide a host of new insights into the etiology and treatment of 
SCZ. The pathophysiology of brain regions known to be involved in 
motor function may help in understanding the disturbed cognitive 
functions in SCZ, given that thinking may be an active motor process. 
Nevertheless, a cure or at least better treatments are sorely needed, and 
a greater understanding of the neurobiology of SCZ is crucial to both 
destigmatizing the illness and advancing clinical care.
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